Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Agios begins dosing in Phase I trial of AG-881 in patients with advanced solid tumors with IDH US-based Agios Pharmaceuticals has dosed first patient in a Phase I trial of single agent AG-881, a small molecule, in patients with advanced solid tumors with an isocitrate dehydrogenas (IDH) mutation. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Arrowhead begins dosing patients in Phase I trial of ARC-AAT to treat AATD
By PBR Staff Writer
US-based Arrowhead Research has started dosing patients in Part B of a Phase I clinical trial of its RNAi-based drug candidate ARC-AAT to treat liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD).
Contract Research & Services > Clinical Trials > News
FDA and NIH grant clearance for VistaGen to initiate AV-101 Phase II MDD trial
By PBR Staff Writer
The US Food and Drug Administration (FDA) and the US National Institutes of Health (NIH) have granted clearance to VistaGen Therapeutics to initiate a Phase II clinical trial of its orally active AV-101 in patients with treatment-resistant major depressive disorder (MDD).
Contract Research & Services > Clinical Trials > News

Contract Research

TES Pharma and EPFL establish R&D collaboration
TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) has formed new research and development collaboration on novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases.
Contract Research & Services > Contract Research > News
Neothetics to evaluate clinical effect of LIPO-202 to reduce central abdominal bulging
By PBR Staff Writer
Neothetics has started the post-treatment safety and duration of effect study, LIPO-202-CL-23, of the first non-invasive injectable drug candidate 'LIPO-202' to reduce central abdominal bulging due to subcutaneous fat in non-obese subjects.
Contract Research & Services > Contract Research > News

Contract Services

Immune Pharma inks license and research deal with Yissum for AmiKet Nano
Immune Pharmaceuticals (IMNP) has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet, pursuant to the parties' existing binding memorandum of understanding from March 2015.
Contract Research & Services > Contract Services > News
Eolas, AstraZeneca to develop orexin-1 receptor antagonist to treat multiple indications
By PBR Staff Writer
US-based Eolas Therapeutics and AstraZeneca have entered into a worldwide license and partnership agreement on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications.
Contract Research & Services > Contract Services > News